

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number  
**WO 01/58949 A2**

(51) International Patent Classification<sup>7</sup>: C07K 14/525,  
C12N 5/02

(74) Agent: LINKKILA, Timothy, P.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(21) International Application Number: PCT/US01/04121

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/181,670 11 February 2000 (11.02.2000) US

(71) Applicant (for all designated States except US): BIO-  
GEN, INC. [US/US]; 14 Cambridge Center, Cambridge,  
MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RENNERT, Paul,  
D. [US/US]; 278 Ridge Street, Millis, MA 02054 (US).  
THOMPSON, Jeffrey, S. [US/US]; 60 Newcomb Road,  
Stoneham, MA 02180 (US). AMBROSE, Christine  
[US/US]; 197 Wakefield Street, Reading, MA 01867 (US).  
CACHERO, Teresa, G. [ES/US]; 105 Longwood Avenue,  
Brookline, MA 02446 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: HETEROLOGOUS POLYPEPTIDE OF THE TNF FAMILY

(57) Abstract: A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as "APBF" has been identified.

WO 01/58949 A2



## HETEROLOGOUS POLYPEPTIDE OF THE TNF FAMILY

### TECHNICAL FIELD

This invention relates, in part, to a newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as "APBF", its variants, derivatives, agonists and antagonists; and uses thereof. In particular, the invention  
5 relates to an APBF having a TNF-family member APRIL subunit linked non-covalently to a TNF-family member BAFF subunit.

### BACKGROUND OF THE INVENTION

Tumor Necrosis Factor (TNF)-family members can best be described as master  
10 switches in the immune system controlling both cell survival and differentiation. Given the current progress in manipulating members of the TNF-family for therapeutic benefit, including anti-tumor activity as well as immune regulation and inflammation, it is likely that members of this family will provide unique means to control disease. The medical utility of the TNF ligands and antagonists to the ligands has been shown for  
15 several systems. Most notable is TNF. TNF controls a wide array of immune processes, including inducing acute inflammatory reactions, as well as maintaining lymphoid tissue homeostasis. Because of the dual role this cytokine can play in various pathological settings, both agonist and antagonist reagents have been developed as modifiers of disease. For example TNF and  $LT\alpha$  (which also signals through the TNF  
20 receptors) have been used as a treatment for cancers, especially those residing in peripheral sites, such as limb sarcomas. In this setting direct signaling by the cytokine through the receptor induces tumor cell death (Aggarwal and Natarajan, 1996. Eur Cytokine Netw 7:93-124). In immunological settings agents which block TNF receptor signaling (eg., anti-TNF mAb, soluble TNF-R fusion proteins) have been used to treat  
25 diseases like rheumatoid arthritis and inflammatory bowel disease. In these pathologies, TNF is acting to induce cell proliferation and effector function, thereby exacerbating autoimmune disease. In this setting blocking TNF binding to its receptor(s) has therapeutic benefit (Beutler, 1999. J Rheumatol 26 Suppl 57:16-21).

A more recently discovered ligand/receptor system appears amenable to similar  
30 manipulations. Lymphotoxin beta ( $LT\beta$ ), a TNF family member which forms heterotrimers with  $LT\alpha$ , binds to the  $LT\beta$ -R. Some adenocarcinoma tumor cells which express  $LT\beta$ -R can be killed or differentiated when treated with an agonistic anti- $LT\beta$ -R mAb (Browning et al., 1996. J Exp Med 183: 867-878). In immunological settings it

-2-

has been shown that anti- LT $\beta$  mAb or soluble receptor fusion protein LT $\beta$ -R-Ig can block the development of inflammatory bowel diseases, possibly by influencing dendritic cell and T cell interaction (Mackay et al., 1998. Gastroenterology 115:1464-1475).

5 In addition to the TNFR and LT $\beta$ -R systems, manipulation of the TRAIL (Gura, 1997. Science 277: 768) and OPG (Simonet et al. 1997. Cell 89: 309-319) pathways may be therapeutically beneficial in treating cancer and bone loss, respectively. Recently, through database searches, there has been a number of newly described members of the TNF family of ligands and receptors. In addition to the number of new  
10 members, the complexity of the ligand/receptor interactions has also increased. It is now apparent that the TNF and LT systems are not unique in the ability of the ligand to interact with more than one receptor. Among the ligands reported to bind more than one receptor or receptor decoy are FasL, TRAIL, RANKL, and LIGHT.

Thus, there is a clear need to identify and characterize additional molecules  
15 which are members of the TNF family thereby providing additional means of controlling disease and manipulating the immune system.

#### SUMMARY OF THE INVENTION

The present invention relates to the identification of a newly discovered heteromer in the TNF-family, APBF, its nucleotide sequences, its protein sequences  
20 and resulting polynucleotides, polypeptides as well as to its soluble form; receptor to the APBF and antibodies specific for APBF and its receptor; and uses therefrom.

The invention relates to an isolated polypeptide comprising an APRIL subunit linked via a non-covalent interaction to a BAFF subunit. In one aspect the invention is directed to an isolated polypeptide comprising an APRIL subunit selected from the  
25 group consisting of human APRIL, partial human APRIL, murine APRIL or partial murine APRIL, or amino acid substitution variants thereof; linked via non-covalent interaction to a BAFF subunit selected from the group consisting of human BAFF, partial human BAFF, murine BAFF or partial murine BAFF, or amino acid substitution variants thereof. In preferred embodiments, the partial BAFF or APRIL polypeptides  
30 are soluble portions of the polypeptides.

In preferred embodiments of the invention, the heterologous polypeptide comprises more than one APRIL subunit, and more preferably two APRIL subunits, linked non-covalently to a BAFF subunit. In alternative embodiments, the

heterologous polypeptide comprises more than one BAFF subunit, and more preferably two BAFF subunits, linked non-covalently to an APRIL subunit. Thus, in preferred embodiments, the present invention is directed to heterologous polypeptide trimers of BAFF and APRIL subunits, in which the ratio of APRIL to BAFF subunits is 2:1, or  
5 alternatively 1:2.

The present invention also relates to therapeutic methods utilizing the heteromers of the invention. One aspect of the invention relates to methods of inhibiting B-cell, T-cell or tumor cell growth in an animal by administering a therapeutically effective amount of a composition selected from the group consisting of  
10 an isolated APBF molecule or active fragment thereof, a recombinant APBF molecule or active fragment thereof, and an antibody specific for APBF or an active fragment thereof. Another aspect of the invention relates to methods of stimulating B-cell or T-cell growth in an animal by administering a therapeutically effective amount of a composition selected from the group consisting of an isolated APBF molecule or active  
15 fragment thereof, a recombinant APBF molecule or active fragment thereof, and an antibody specific for APBF or an active fragment thereof.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings depicts certain embodiments of the invention. They are illustrative only and do not limit the invention otherwise disclosed herein.

20 Figure 1a shows the amino acid sequence of human APRIL. The predicted transmembrane region (TM, boxed), the potential N-linked glycosylation site (star) and the N-terminus of the recombinant soluble APRIL sequences are indicated. Figure 1b shows the DNA sequences encoding human APRIL (SEQ ID NO. 1). Figure 1c shows the amino acid sequence of human APRIL (SEQ ID NO. 2). Figure 1d shows the DNA  
25 sequences encoding mouse APRIL (SEQ ID NO. 3). Figure 1e shows the amino acid sequence of mouse APRIL (SEQ ID NO. 4).

Figure 2a shows the DNA sequences encoding human BAFF (SEQ ID NO. 5). Figure 2b shows the amino acid sequence of human BAFF (SEQ ID NO. 6). Figure 2c shows the DNA sequences encoding mouse BAFF (SEQ ID NO. 7). Figure 2d shows  
30 the amino acid sequence of mouse BAFF (SEQ ID NO. 8). Amino acids 1 to 46 from SEQ ID NO. 6 represent the intracellular domain, amino acids 47 to 72 from SEQ ID NO. 6 represent the transmembrane domain and amino acids 73 to 285 from SEQ ID NO. 6 represent the extracellular domain.

Figures 3a and 3b show a comparison of two western blots from cells co-transfected with various APRIL and BAFF encoding plasmids. The detection reagent used in Figure 3a is an anti-FLAG antibody. The detection reagent used in Figure 3b is an anti-BAFF antibody.

Figure 4 shows a western blot of the immunoprecipitations of conditioned media from cells co-transfected with plasmids encoding various soluble APRIL and soluble BAFF proteins and immunoprecipitated with an anti-FLAG-tagged antibody. The detection reagent for the western blot is an anti-myc tagged antibody.

#### DETAILED DESCRIPTION

##### Definitions

The term "APBF" or "APBF ligand" when used herein encompasses any native or recombinantly produced polypeptide having an APRIL subunit linked via a non-covalent interaction to a BAFF subunit. APBF may be isolated from a variety of sources, such as from murine or human tissue types or from other sources, or prepared by recombinant or synthetic methods. A large number of analytical biochemistry methods, known to those of skill in the art, can be utilized to determine the stoichiometry of APBF, its variants and derivatives. For example, cation exchange chromatography can be used to determine which of the various stoichiometric forms are present in the preparation derived from affinity columns. Also gel chromatography of the purified fractions will show the molecular weights of each form. The molecular weights of APRIL and BAFF are known. For example, the molecular weight of full length human BAFF, amino acids 1-285, is predicted to be 34.2kDa for each polypeptide. The molecular weight of soluble human BAFF, amino acids A132-285, is predicted to be 18.2kDa per polypeptide. The molecular weight of full length human APRIL, amino acids 1-250, is predicted to be 30.0kDa for each polypeptide. The molecular weight of soluble human APRIL, amino acids A105-250, is predicted to be 17.5kDa per polypeptide. Stoichiometric combinations contemplated in the present invention include the following formula, X APRIL: Y BAFF, where X and Y are integers greater than or equal to one. It is contemplated that the heteromer may exist as a soluble molecule, wherein all subunits are of soluble APRIL or BAFF polypeptides. It is further contemplated that the heteromer may exist as a cell associated molecule, wherein at least one of the subunits is the full length molecule containing a transmembrane domain and the other subunit(s) may contain either full length or soluble forms of APRIL or BAFF.

-5-

The term "APRIL subunit" when used herein encompasses any native or recombinantly produced APRIL polypeptide. The APRIL subunit may be isolated from a variety of sources, such as from murine or human tissue types or from other sources, or prepared by recombinant or synthetic methods. For example, an APRIL subunit can have an amino acid sequence encoded by human APRIL (SEQ ID 1) or murine APRIL (SEQ ID 2) and variants, derivatives and unique fragments thereof. Specifically contemplated are human and murine soluble construct forms of APRIL (SEQ ID NO \_ and SEQ ID NO \_, respectively) and variants, derivatives and unique fragments thereof.

The term "BAFF subunit" when used herein encompasses any native or recombinantly produced BAFF polypeptide. The BAFF subunit may be isolated from a variety of sources, such as from murine or human tissue types or from other sources, or prepared by recombinant or synthetic methods. For example, a BAFF subunit can have an amino acid sequence encoded by human BAFF (SEQ ID \_) or murine BAFF (SEQ ID \_) and variants, derivatives and unique fragments thereof. Specifically contemplated are human and murine soluble construct forms of BAFF (SEQ ID NO \_ and SEQ ID NO \_, respectively) and variants, derivatives and unique fragments thereof.

As defined herein, a "unique fragment" of a protein or nucleic acid is a peptide or oligonucleotide of sufficient length to have a sequence unique to a particular gene or polypeptide, i.e., a sequence not shared by related or unrelated genes or polypeptides. Thus, for example, a unique nucleic acid fragment typically will have at least 16 nucleotide residues, and a unique polypeptide fragment typically will have at least 6 amino acid residues. Preferably, to ensure substantially unique occurrence in a typical higher eukaryotic genome, a unique nucleic acid fragment should have at least 20 nucleotide residues, and a unique polypeptide fragment should have at least 8 amino acid residues.

An "isolated" polypeptide, polynucleotide, protein, antibody, or other substance refers to a preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar substance naturally occurs or is initially obtained from. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source mixture. Increasing enrichments of the embodiments of this invention are increasingly

-6-

more preferred. Thus, for example, a 2-fold enrichment is preferred, 10-fold enrichment is more preferred, 100-fold enrichment is more preferred, 1000-fold enrichment is even more preferred. A substance can also be provided in an isolated state by a process of artificial assembly, such as by chemical synthesis or recombinant expression.

5        "Hybridization" is the noncovalent, antiparallel bonding of complementary nucleic acid strands, in which Watson-Crick base pairing is established. To ensure specificity, hybridization should be carried out under stringent conditions, defined herein as conditions of time, temperature, probe length, probe and/or target concentration, osmotic strength, pH, detergent, carrier nucleic acid, etc. that permit no  
10 more than an occasional base-pairing mismatch within a probe/target duplex. Highly stringent conditions exclude all but about one base pair mismatch per kb of target sequence. Exemplary highly stringent conditions involve hybridization to membrane immobilized target nucleic acid at a temperature of 65°C in the presence of 0.5 M NaHPO<sub>4</sub>, 7% SDS, 1mM EDTA, followed by washing at 68°C in the presence of 0.1x  
15 SSC, 0.1% SDS. Current Protocols in Molecular Biology (1989), Ausubel et al., eds, Greene Publishing and Wiley Interscience, New York, NY. In circumstances where relatively infrequent mismatches, e.g., up to about ten mismatches per kb of target, can be tolerated, moderately stringent conditions may be used. For moderate stringency, probe/target hybrids formed under the above conditions are washed at 42°C in the  
20 presence of 0.2x SSC, 0.1%SDS.

An "individual" is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats.

An "effective amount" is an amount sufficient to effect beneficial or desired  
25 clinical results. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount is an amount of APBF, variants and derivatives of APBF and agonists and antagonists of APBF that is sufficient to ameliorate, stabilize, or delay development of a disease state associated with APBF. Particularly APBF-associated tumors. Detection and measurement of  
30 these indicators of efficacy are discussed below.

As used herein, "treatment" is an approach for obtaining beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviation of symptoms,

-7-

diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread (i.e., metastasis) of disease, preventing occurrence or recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, and remission (whether partial or total). Also encompassed by "treatment" is a reduction of pathological consequences of an APBF-associated tumor(s).

As used herein, the term "cancer" refers to any neoplastic disorder, including such cellular disorders as, for example, renal cell cancer, Kaposi's sarcoma, chronic leukemia, breast cancer, sarcoma, ovarian carcinoma, rectal cancer, throat cancer, melanoma, colon cancer, bladder cancer, mastocytoma, lung cancer, mammary adenocarcinoma, pharyngeal squamous cell carcinoma, and gastrointestinal or stomach cancer. Preferably, the cancer is leukemia, mastocytoma, melanoma, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.

To determine the "percent homology" of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100). The determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77.

The invention encompasses all nucleic acids, peptides, polynucleotides, polypeptides and proteins of the present invention that can be produced, expressed, and/or manipulated by conventional molecular engineering techniques such as the techniques set forth in Current Protocols in Molecular Cloning, Ausubel et al., eds. (1989), Greene Publishing and Wiley Interscience, New York, NY and in Sambrook et



-8-

al. (1989), Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, and the teachings described and referenced in Watson et al. (1992), Recombinant DNA 2nd ed., Scientific American Books and W.H. Freeman & Co., New York, NY.

5     Description of the Invention

The present invention relates to a newly identified heteromeric member of the TNF-family, APBF, wherein APBF comprises an APRIL subunit linked non-covalently to a BAFF subunit.

APRIL, a TNF ligand known to have a role in inducing tumor cell proliferation  
10     is described in detail in PCT publications WO99/12965, WO97/33902, WO99/50416 and U.S. Provisional Application Serial No. 60/106,976, each incorporated by reference herein. It has been shown that high levels of APRIL mRNA are detected in several tumor cell lines, as well as in colon carcinomas, metastatic lymphomas and thyroid tumors. Moreover, it has been shown that the *in vitro* addition of recombinant APRIL  
15     stimulates the proliferation of various cell lines. It is also recognized that in addition to inducing tumor cell proliferation that APRIL may modulate a variety of functions of immune system cells *in vitro* and *in vivo* (Hahne et al., (1998) J. Exp. Med. 188 :1185-1190).

The second component of APBF, BAFF, has been shown to have a role in  
20     inducing the proliferation of naïve B cells and is described in detail in PCT publications WO98/18921, WO98/27114, and WO99/12964, each incorporated by reference herein. Like APRIL, BAFF has also been shown to modulate a variety of functions of immune system cells *in vitro* (Schneider et al., (1999) J. Exp. Med. 189: 1747-1756) and *in vivo* (Mackay et al., (1999) J. Exp. Med.190:1697-1710; Moore et al., (1999) Science.285:  
25     260-263).

To date, all known TNF-family members, with the exception of the lymphotoxins, form homomers. It was therefore a surprising discovery, as a result of the work described herein, to identify a heteromeric polypeptide having an APRIL subunit linked non-covalently to a BAFF subunit. Figures 1 and 2 provides the full  
30     length and partial nucleic acid and amino acid sequences of mammalian APRIL and mammalian BAFF, respectively. The intracellular, transmembrane, and extracellular domains are identified, and a protease cleavage site is marked. N-terminal amino acid sequence analysis of APRIL secreted into the media of EBNA293 cells transfected with

-9-

the full length murine APRIL cDNA plasmid identified alanine at position 87 as the first amino acid in the secreted form. Similar analysis of human BAFF overexpressed in EBNA293 cells showed that alanine at position 134 (numbering of amino acids corresponds to the naturally occurring human BAFF sequence, as found for example, in Schneider et al. 1999 *J. Exp. Med* 189: 1747-1756) was the first amino acid of the secreted form through amino acid 285.

In one embodiment, APBF comprises an APRIL subunit derived from a mammalian APRIL linked via a non-covalent interaction to a BAFF subunit derived from a mammalian BAFF. It is contemplated that subunits of APRIL and/or BAFF may remain cell membrane bound via their transmembrane domains, and comprise part of a membrane-bound APBF. Alternatively, the APBF may consist of the natively cleaved forms of APRIL and BAFF extracellular domains, or fragments derived from the natively cleaved forms. As illustrated in Example 1, when FLAG-tagged soluble APRIL is co-expressed with full-length BAFF, the soluble heteromeric complex is formed. This shows that the full-length BAFF is readily cleaved and complexes with the artificially generated soluble APRIL molecule. Alternatively, Example 2 demonstrates that the complex can be formed when both APRIL and BAFF are expressed as soluble molecules. This indicates that the region between the transmembrane and receptor binding domain (stalk) is not required for association. However, if one or more subunits remains uncleaved then the complex will remain tethered to the cell surface. Alternatively, the complex will be secreted. Since additional modification may take place after proteolytic cleavage from the cell surface, other subunit forms are envisioned, for example, one or more subunits may consist of a portion of the extracellular domain, as when the stalk portion (before the first beta sheet) is shortened. Also, as APRIL and BAFF contain glycosylation sites it is conceivable that one or more subunits may be aglycosylated or differentially glycosylated. Such modifications may depend on the cell in which the heteromer is expressed.

As a result of the work described herein, in which we identified APBF by co-expression and differentially tagging (see Examples 1 and 2), we are able to produce and isolate APBF by any of a number of techniques known to those of skill in the art, including for example, affinity methods, as described for example, in Example 3. Another example of a known method for isolation of proteins include ion exchange

-10-

chromatography. For example, APBF may easily be separated by ion exchange chromatography based on the widely ranging pI values for soluble human APRIL (ie: hAPRIL pI=9.81) and soluble human BAFF (hBAFF pI=4.75). Heterocomplexes commonly have pI values that are additive in nature. Stoichiometrically different combinations of BAFF and APRIL proteins would be expected to bind DEAE and S-sepharose columns with significantly different affinities at a given pH. Visualization of these heterocomplexes can also be done by isoelectric focusing (IEF), followed by blotting and detection with antibodies. IEF can also be used to isolate small amounts of proteins. Since native IEF generally does not disrupt protein function it may well present itself as a useful way to assay the protein binding affinities cells and receptors and to evaluate transfections for the level of the various heteromers produced. Such methods are particularly useful in separating different subunit stoichiometries which may be present after co-transfection.

The invention further provides degenerate variant nucleic acids that encode the SEQ ID No: 1 and 2 polypeptides or a unique fragment thereof. In yet further embodiments, the invention provides nucleic acids encoding variant APBF polypeptides, comprising amino acid sequences sharing at least 75% sequence similarity with the SEQ ID Nos. 1 and 2. Preferably, these nucleic acids encode polypeptides sharing at least 80%, 85%, 90% or more preferably 95% amino acid sequence similarity with SEQ ID Nos. 1 and 2. The encoded variant polypeptides comprise amino acid mutations (substitutions, deletions and/or insertions) distributed in any random or non-random frequency within SEQ ID Nos. 1 and 2. "Similarity" as used herein refers to the sum of aligned amino acid residues that are identical to the residues of corresponding SEQ ID Nos. 1 and 2 and those that are allowed point mutations therefor. Moderate gaps and/or insertions (e.g., less than about 50, preferably less than about 15, more preferably less than about 5 amino acid residues) in the aligned sequence are ignored for similarity calculation purposes. Allowed point mutations are substitutions by amino acid residues that are physically and/or functionally similar to the corresponding aligned residues of SEQ ID Nos. 1 and 2, e.g., that have similar size, shape, hydrophilic or hydrophobic character, charge and chemical properties.

It should be understood that the present invention provides oligonucleotides that hybridize to any of the foregoing variant APBF nucleic acids, i.e., to nucleic acids that

-11-

encode polypeptides comprising amino acid sequences that share at least 75% sequence similarity with SEQ ID Nos. 1 and 2. More particularly, the invention provides oligonucleotides that hybridize to one or more unique fragments of nucleic acids encoding APBF. For therapeutic purposes and/or for PCR investigative or diagnostic purposes, the present oligonucleotides hybridize to a unique fragment comprising 5' untranslated sequence, a transcription initiation site, ORF or polypeptide coding sequence, intron-exon boundary, polyadenylation site or 3' untranslated region of the present APBF nucleic acids.

The invention also relates to heteromers formed with partial sequences of human and murine APRIL and human and murine BAFF. Preferably, these partial sequences comprise soluble forms of BAFF and APRIL. Preferred partial human APRIL molecules include amino acids A105 to L250, K110 to L250 and H115 to L250 of the full-length human APRIL sequence. Preferred partial murine APRIL molecules include amino acids A87 to L233 of the full-length murine APRIL sequence. Preferred partial human BAFF sequences include amino acids A134 to L285 and Q136 to L285 of the full-length human BAFF sequence (see, Schneider et al. 1999, J.Exp. Med. 189:1747-1756, incorporated by reference herein).

Preferred partial sequences of human and murine APRIL and BAFF also include splice variants of APRIL and BAFF. A preferred partial human APRIL sequence includes a splice variant that is the complete APRIL human sequence missing amino acids 113 to 128 (see, Kelly et al. 2000, Can. Res. 60: 1021-1027, incorporated herein by reference). Preferred partial human BAFF sequences include a splice variant which is the full-length BAFF sequence missing amino acids 142 to 160 (see, WO 00/50597). Preferred partial murine BAFF sequences include a splice variant which is full-length BAFF sequence missing amino acids 166 to 184.

The invention also encompasses soluble secreted forms of APBF. See Example 2. To create a soluble secreted form of APBF, one would use techniques known to those of skill in the art, including for example removing at the DNA level the N-terminus transmembrane regions encoding either the APRIL and/or BAFF N-terminus transmembrane regions, and some portion of the corresponding stalk region, and replace these regions with a type I leader or alternatively a type II leader sequence that will allow efficient proteolytic cleavage in the chosen expression system. A skilled artisan could vary the amount of the stalk region retained in the secretion expression

-12-

construct to optimize both receptor binding properties and secretion efficiency. For example, the constructs containing all possible stalk lengths, i.e. N-terminal truncations, could be prepared such that proteins starting at amino acids 105-135, for APRIL and 134-164 for BAFF would result. The optimal length stalk sequence would  
5 result from this type of analysis.

Isolated APBF can be used for a number of purposes, such as the production of monoclonal or polyclonal antibodies, and identification of novel modulators affecting biological function (e.g., inhibitors), and identification of receptors interacting with APBF.

10 As a result of the work described herein, antibodies (polyclonal or monoclonal) specific for the identified APBF can be produced, using known methods (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). Such antibodies and host cells (i.e. hybridoma cells) producing the antibodies are also the subject of the present invention.

15 Antibody production involves administration of one or more immunogenic doses of an APBF polypeptide preparation (whether isolated or incorporated in a cell membrane) to an appropriate non-human animal, such as a mouse, rat, rabbit, guinea pig, turkey, goat, sheep, pig, or horse. To enhance immunogenicity, the preparation can be emulsified with a conventional adjuvant, such as Freund's complete or incomplete  
20 adjuvant. Routine monitoring of serum immunoglobulins, using peripheral blood samples withdrawn at appropriate intervals (e.g., seven to ten days) after an initial or subsequent immunization, can be used to detect the onset and/or maturation of a humoral immune response. Detection and, optionally, quantitation, of immunoglobulins selectively reactive with an APBF epitope can be achieved through  
25 any conventional technique, such as ELISA, radioimmunoassay, Western blotting, or the like.

An immunoglobulin "selectively reactive with an APBF epitope" has binding specificity for the recognized epitope such that an antibody/epitope complex forms under conditions generally permissive of the formation of such complexes (e.g., under  
30 conditions of time, temperature, ionic strength, pH ionic or nonionic detergent, carrier protein, etc.). Serial dilution (titration) analysis by standard techniques is useful to estimate the avidity of antibodies in the immune serum sample for one or more epitopes unique to APBF. As defined herein, an "epitope unique to APBF" is a unique,

-13-

immunogenic fragment of the full-length APBF polypeptide. A unique linear epitope typically ranges in size from about ten to about twenty-five amino acid residues, and frequently is about twelve to eighteen residues in length.

Immune serum having a high titer generally is preferred herein. Serum having a half maximal avidity for a unique APBF epitope of at least about 1:1000, preferably at least about 1:10,000, can be harvested in bulk for use as a source of polyclonal antibody useful in the detection and/or quantitation of APBF. Polyclonal immunoglobulins can, if desired, be enriched by conventional fractionation of such serum, or can be isolated by conventional immunoadsorbent techniques, e.g., using a Protein A or Protein G chromatography resin. Immune, high titer murine, rat, hamster or guinea pig serum alternatively is preferred herein for the production and screening of hybridomas secreting monoclonal antibodies selectively reactive with APBF. The present hybridomas can be produced according to well-known, standard techniques. The present monoclonal antibodies can be obtained from hybridoma culture supernatant, or from conventionally produced ascites fluid, and optionally isolated via immunoadsorbent chromatography or another suitable separation technique prior to use as agents to detect and/or quantitate APBF.

A preferred antibody, whether polyclonal or monoclonal, is selectively reactive with a unique APBF epitope that is displayed on the surface of or secreted from APBF expressing cells. The preferred antibody accordingly can be used to detect and, if desired, quantitate APBF expressing cells, e.g., normal or transformed cells in a mammalian body tissue or biopsy sample thereof. Specifically, the preferred antibody can be used to detect APBF expressing cells whether such cells are host cells or mammalian body tissue cells that aberrantly express APBF. Advantageously, intact, e.g., living, cells that display a unique APBF epitope can be detected by standard immunohistochemical, radiometric imaging or flow cytometry techniques. The present antibody can be used to detect and/or monitor APBF polypeptide production. Thus, the antibody can be used to assess the natural tissue-specific production of APBF, and thus to assess tissues likely to give rise to carcinomas or sarcomas. In addition, the present antibody can be used to monitor tumor biopsy samples to provide information relevant to selecting or revising a course of disease management, or to diagnosis, prognostication and/or staging of any disease associated with an abnormality affecting APBF. Furthermore, the present antibody can be used in a cell-sorting procedure or

-14-

other cell isolation procedure to generate a substantially pure preparation of APBF expressing cells, or a cell population substantially depleted of APBF expressing cells. Each of the foregoing can be achieved through routine practice or modification of well-known techniques, including but not limited to the conjugation of a detectable moiety (e.g., a radionuclide, fluorophore, chromophore, binding pair member, or enzyme) to the APBF reactive antibody.

A hybridoma secreting an APBF reactive monoclonal antibody of the present invention additionally provides a suitable source of nucleic acid for the routine construction of a fusion polypeptide comprising an antigen-binding fragment derived from the APBF reactive antibody. The present fusion polypeptide can be prepared by routine adaptation of conventional techniques described in Deeley et al. (1996), U.S. Patent 5,489,519 (incorporated herein by reference). The fusion polypeptide can be a truncated immunoglobulin, an immunoglobulin having a desired constant region (e.g., IgG in lieu of IgM), or a "humanized" immunoglobulin having an APBF reactive Fc region fused to a framework region of human origin. Additional fusion polypeptides can comprise, in addition to an APBF reactive antigen-binding fragment, a non-immunoglobulin polypeptide such as a cytotoxic polypeptide (e.g., diphtheria toxin, ricin) or a chemoattractant polypeptide that stimulates immune effector cells (cytotoxic T cells, natural killer cells, macrophages) to kill cells that display APBF. Standard techniques well-known in the art can be used to produce appropriate immunoglobulin fusion polypeptides of the present invention.

Various forms of antibodies can also be made using standard recombinant DNA techniques. For example, humanization techniques have been developed that render non-human Mabs less antigenic in humans. Methods for humanizing Mabs by chimerisation procedures are described in EP0120694, EP0125023, EP-A-0 171496, EP-A-0173 494 and WO 86/01533, each incorporated by reference herein. Chimerisation procedures generally involve preparing antibody having the variable domains from a mouse MAb and the constant domains from a human immunoglobulin. Alternatively, methods for humanizing Mabs by CDR-grafting are described in EP-A-0239400 (Winter), WO90/07861 (Queen), WO91/09967 (CellTech), and WO91/09967 (CellTech), incorporated by reference herein. CDR-grafting generally involves grafting the complementarity determining regions (CDRs) of a mouse MAb onto the framework regions of the variable domains of a human immunoglobulin by site directed

-15-

mutagenesis using long oligonucleotides. In WO91/09967, the preparation of humanized CDR-grafted antibody products which have specificity for TNF-alpha is described. In particular WO91/09967 describes in Example 5, preparation of specific humanized CDR grafted antibodies to human TNF-alpha derived from murine anti-human TNF-alpha Mabs. Using any of these known methods, therefore, antibodies specific for APBF can be produced and isolated.

The polypeptides and methods disclosed herein enable the identification of receptors which specifically interact with APBF or fragments thereof. For example, the APBF receptor can be cloned using any of the techniques known to those of skill in the art, including for example, one or more of the following approaches.

For example, one can identify an APBF receptor using expression cloning in mammalian cells. Specifically, a cDNA expression library is generated from a cell line or cell population shown to express the highest level of the receptor to the protein of interest, i.e. APBF. This approach was shown for the leptin receptor (Tartaglia et al., 1995 Cell 83: 1263-1271). The cDNA library DNA is made as pools of 2-3,000 cDNAs and transfected into an appropriate cell line which does not express the receptor. A plate assay format may be used to detect expression of the receptor on the surface of the receptor negative cell line using purified APBF. An antibody to one of the subunits or to an epitope tag is used to detect the bound protein of interest, i.e. APBF and an alkaline phosphatase conjugated secondary antibody and alkaline phosphatase substrates are used to visualize the positive cells. The plate wells are screened using a microscope. The complexity of the cDNA pools from the positive wells are reduced and then screened again. The screening continues until transfection of a single cDNA produces a positive signal. The DNA of the cDNA is sequenced and the predicted amino acid sequence analyzed for motifs and structure consistent with members of the TNF receptor family. Other expression cloning formats are available, for example, by panning on ligand coating plates, or by sorting with tagged ligand in FACS analyses.

In another approach, one can identify an APBF receptor using direct DNA sequence analysis. Specifically, a directional cDNA library is generated from a receptor positive cell line and the 5' ends sequenced using ABI automated DNA sequencing technology to determine the open reading frame. Programs to look at the cysteine residue spacing, signal and transmembrane sequences can be employed to



-16-

identify potential TNF receptor family members. Full-length clones will then be isolated, expressed and examined for the ability to bind APBF. The library can also be subtracted with a APBF receptor negative cell line to reduce the complexity of the library.

5           In another approach, one can identify an APBF receptor by examining known or orphan receptors. Specifically, purified APBF can be used in FACS, immunoprecipitation, ELISA or Biacore assays against a panel of orphan receptors and those that have known ligands. A receptor for APBF will be positive in all of these assays.

10           In yet another approach, one can identify an APBF receptor using protein sequence analysis methods. Specifically, APBF can be cross-linked to the surface of cells determined to be receptor positive using standard reagents. The cross-linked complex can be immunoprecipitated using an antibody to one of the subunits or an epitope tag on the subunit. The complex can be separated on a SDS polyacrylamide,  
15           blotted to a membrane and subjected to amino acid analysis. Once amino acid sequencing reveals information about the receptor, degenerate oligonucleotide probes can be synthesized and used to screen a cDNA library made from a receptor positive cell line.

            Alternatively, one can identify an APBF receptor using known biochemical  
20           approaches in combination with mass spectrometry to specifically identify masses and sequences. Three illustrative examples are set forth below:

            Strategy 1: Binding of [125I]-labelled APBF to different cell lines. After choosing the appropriate cell line, crosslinking of [125I]-APBF to the cells followed by polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography will reveal a  
25           receptor protein that will be analyze by mass spectrometry.

            Strategy 2: Crosslinking of [125I]-labelled APBF to cell lines, followed by immunoprecipitation using specific antibodies and polyacrylamide gel electrophoresis.

            Strategy 3. Choosing appropriate cell lines that bind APBF. Adding purified APBF would allow the heteromer binding to the receptor. Immunoprecipitation using  
30           specific antibodies to the heteromer followed by SDS-PAGE and autoradiography will reveal specific bands that will be isolated and analyzed by mass spectrometry to identify the receptor/s.

-17-

The foregoing compositions can be used for a number of purposes, including the assessment (e.g., for diagnostic purposes) of abnormalities in the structure and/or expression of a cellular APBF gene as well as diagnosis of conditions involving abnormally high or low expression of APBF activities. For example, in WO/99/12965, it was shown that while transcript of APRIL are of low abundance in normal tissues, high levels of mRNA are detected in several tumor cells lines. The expression and growth stimulating effect of APRIL on tumor cells suggested a role for APRIL in tumorigenesis. Similarly, the monitoring of APBF transcript or polypeptide production, or gene expression level, or fluctuations therein, in one or more tumor biopsy samples is expected to provide information relevant to diagnosis, prognostication and/or staging of neoplastic disease in a cancer sufferer.

Any suitable means for detecting APBF transcript or polypeptide production or stabilization, or gene expression level, can be applied for the present diagnostic purposes. Appropriate methods are described in Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Standard methods of analysis allow the detection of activity by cells in response to ligand binding. For example preparations of the APBF heteromer will be useful in analyses of cellular proliferation, differentiation, and apoptosis. Numerous cell types can be rapidly screened in such a manner using standard methods such as radioactive-thymidine incorporation, cell cycle analysis, and MTT uptake and conversion (detailed in Celis et al., Cell Biology, A Laboratory Handbook, Volume One, Academic Press, San Diego, CA (1997)). Other methods of analysis that can be used to assess activity include protein phosphorylation analysis, for example, of Nuclear Factor  $\kappa$ B transcription factor (NF $\kappa$ B) or c-Jun N-terminal Kinase (JNK) (eg., Mackay et al., *J. Biol. Chem.* 271: 24934-24938 (1996); Wong et al., *J. Biol. Chem.* 272: 25190-25194 (1997)). Other readily accessible assays include measurements of cytokine secretion (eg. IL-8: Chicheportiche et al., *J. Biol. Chem.* 272: 32401-32410 (1997)), calcium flux, pH change, cell/cell adhesion, etc (with references).

In addition to these readouts, analyses of upregulated or downregulated genes are readily done, for, by example, Northern blot, targeted array, or gene array analyses (eg. Teague et al., *Proc. Natl. Acad. Sci. USA* 96:12691-12696 (1999); Lockhart et al., *Nat. Biotechnol.* 14: 1675-1680 (1996)). Such differential gene expression studies

-18-

identify specific sets of genes which respond to ligand activity, and can provide detailed profiles of ligand function (eg. Jiang et al., Oncogene 11: 1179-1189 (1995)). Particularly sensitive to such analyses are modifiers of cell growth, eg. growth hormone receptor genes, transcription factors, genes whose proteins induce or block cell death, and cell cycle mediators, among many others.

The present invention is useful for diagnosis or treatment of various immune system-related disorders in mammals, preferably humans. Such disorders include but are not limited to cancer, including, but not limited to, cellular disorders as, for example, renal cell cancer, Kaposi's sarcoma, chronic leukemia, breast cancer, sarcoma, ovarian carcinoma, rectal cancer, throat cancer, melanoma, colon cancer, bladder cancer, mastocytoma, lung cancer, mammary adenocarcinoma, pharyngeal squamous cell carcinoma, and gastrointestinal or stomach cancer. Additionally, the present invention is useful for the treatment of proliferative conditions that are not considered to be tumors, i.e. cellular hyperproliferation (hyperplasia), such as, for example, scleroderma, pannus formation in rheumatoid arthritis, postsurgical scarring and lung, liver and uterine fibrosis. In addition, the present invention is useful for the treatment of immunodeficiencies, inflammatory diseases, lymphadenopathy, autoimmune diseases, and graft versus host disease.

In one embodiment, conditions caused by a decrease in the normal level of APBF activity in an individual can be treated by administration of APBF or an agonist to APBF, where an agonist to APBF refers to any natural or synthetic composition which potentiates function, where function refers to any measurable effect of APBF interaction with cells, tissues or organisms, as measured in any known *in vitro* or *in vivo* assays, which is mediated by APBF. In one embodiment, APBF is in soluble form. The invention also provides a method of treatment of disorders caused by an increase in the normal level of APBF activity in an individual by administration of an antagonist to APBF, where an antagonist to APBF refers to any natural or synthetic composition that blocks function, where function refers to any measurable effect of APBF interaction with cells, tissues or organisms, as measured in any known *in vitro* or *in vivo* assays, which is mediated by APBF heteromers.

Pharmaceutical compositions of the invention may comprise a therapeutically effective amount of APBF, or its receptor, or fragments or mimetics thereof, and, optionally may include pharmaceutically acceptable carriers. Accordingly, this

-19-

invention provides methods for treatment of cancer, and methods of stimulating, or in certain instances, inhibiting the immune system, or parts thereof by administering a pharmaceutically effective amount of a compound of the invention or its pharmaceutically acceptable salts or derivatives. In certain preferred embodiments, the invention relates to methods for inhibiting B-cell growth, T-cell growth or tumor cell growth by administering a therapeutically effective amount of an isolated APBF polypeptide or active fragment thereof, or a recombinant APBF molecule or active fragment thereof, or an antibody specific for APBF or active fragment thereof. In the context of this invention "inhibition" relates to any and all mechanisms for reducing or ameliorating activity, including inducing cell death (apoptosis). It should of course be understood that the compositions and methods of this invention can be used in combination with other therapies for various treatments.

The compositions can be formulated for a variety of routes of administration, including systemic, topical or localized administration. For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous for injection, the compositions of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compositions may be formulated in solid form and, optionally, redissolved or suspended immediately prior to use. Lyophilized forms are also included in the invention.

The compositions can be administered orally, or by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art, and include, for example, for transmucosal administration, bile salts, fusidic acid derivatives, and detergents. Transmucosal administration may be through nasal sprays or using suppositories. For oral administration, the compositions are formulated into conventional oral administration forms such as capsules, tablets, and tonics. For topical administration, the compositions of the invention are formulated into ointments, salves, gels, or creams as known in the art.

The dose and dosing regimen will depend on the type of disease, the patient and the patient's history. In one embodiment the disease is cancer. The amount must be effective to treat, suppress, or alter the progression of the disease. The doses may be single doses or multiple doses. If multiple doses are employed, as preferred, the

-20-

frequency of administration will depend, for example, on the type of host and type of disease, dosage amounts etc. For some types of cancers or cancer lines, daily administration will be effective, whereas for others, administration every other day or every third day will be effective. The amount of active compound administered at one time or over the course of treatment will depend on many factors. For example, the age and size of the subject, the severity and course of the disease being treated, the manner and form of administration, and the judgments of the treating physician. However, an effective dose may be in the range of from about 0.005 to about 5 mg/kg/day, preferably about 0.05 to about 0.5 mg/kg/day. The dosage amount which will be most effective will be one which results in no tumor appearance or complete regression of the tumor, and is not toxic to the patient. One skilled in the art will recognize that lower and higher doses may also be useful.

### EXAMPLES

#### Example 1

This example describes the detection of APRIL and BAFF heteromers by immunoprecipitation following co-transfection into mammalian cells.

#### Methods:

The plasmids encoding FLAG-tagged human soluble APRIL, beginning with residue A105 (LT033) or K110 (PL448), soluble FLAG-tagged human TWEAK beginning at A106 (PS288) or soluble FLAG-tagged human EDA beginning at A242 (PS548) or empty vector (CH269) were co-transfected with a full-length human BAFF construct (PS544) into 293T cells using lipofectamine (Life Technologies). At 48 hrs. post-transfection, conditioned media was collected and used for immunoprecipitation experiments. The immunoprecipitation samples contained 200  $\mu$ l of conditioned media, 5  $\mu$ g/ml of the anti-FLAG antibody M2 (Sigma) and 800  $\mu$ l of DMEM containing 10% FCS, glutamine, Pen-Strep, G418 and sodium azide and were incubated at 4°C for 1 hour, with agitation. Then, 30  $\mu$ l of ProteinA-Sepharose beads (Pharmacia) was added to the samples and the mixture was incubated overnight at 4°C with agitation. The beads were collected by centrifugation and then washed one time with the DMEM media described above and then 3 times with PBS. The final pellet containing the beads was then suspended in 2 X SDS non-reducing sample buffer and boiled for 5 minutes. The beads were spun out and 25  $\mu$ l of the supernatant was loaded onto 2 separate 4-20% SDS-PAGE gradient gels (Novex). In order to examine the

-21-

level of ligand expression, non-immunoprecipitated conditioned media from the co-transfected cells were also loaded. These samples were diluted two fold with 2 X non-reducing sample buffer, boiled for 2 min. and then 25 µl was loaded into each lane. Each gel contained a set of immunoprecipitations and a set of non-immunoprecipitated conditioned media. After the gels were transferred to Immobilon (Millipore) filters using a BioRad apparatus, the filters were blocked in 5% non-fat dry milk diluted in TBST for 1 hr at room temperature. The filters were then separated and one was incubated with 5 µg/ml of the biotinylated anti-FLAG antibody, M2 and the other was incubated with 1 µg/ml of an anti-human BAFF antibody 53.14 (rat IgM) for about 1hr at room temperature. The filters were washed with 3 changes of TBST and then incubated in a 1:3000 dilution of streptavidin-HRP or anti-rat IgM-HRP (Jackson ImmunoResearch) for 30 min. at room temperature. The filters were again washed 3 times and then detected using ECL reagents (Amersham). The filters were exposed to x-ray film for various lengths of time.

The results of the co-expression experiment are shown in Figure 3. Panel A, lanes 1-5, show western blots of straight conditioned media from cells co-transfected with various human soluble TNF family ligands and human full length BAFF encoding plasmids. Panel A, lanes 7-12, show western blots of the straight supernatant after immunoprecipitation with an anti-FLAG antibody. The detection reagent used in Panel A is an anti-FLAG antibody. Lane 1: FLAG-tagged human soluble APRIL A105 (beginning at residue A105) + human full length BAFF; Lane 2: FLAG-tagged human soluble APRIL K110 (beginning at residue K110) + human full length BAFF; Lane 3: FLAG-tagged human soluble TWEAK + human full length BAFF; Lane 4: FLAG-tagged human EDA + human full length BAFF; Lane 5: empty control vector; Lane 6: molecular weight standards (Benchmark, LifeTechnologies) in kDa, 185, 119, 85, 62, 51, 38.2, 26.0, 20.2, 14.5, 9.1; Lane 7-11 correspond to Lanes 1-5, respectively, after immunoprecipitation with an anti-FLAG antibody; Lane 12: purified human FLAG-BAFF Q136, 5ng.

Panel B, lanes 1-5, show western blots of straight supernatant from cells co-transfected with various APRIL and BAFF encoding plasmids. The detection reagent is an anti-BAFF antibody. Panel B, lanes 7-11 show western blots of immunoprecipitates in which cells were co-transfected with various APRIL and BAFF encoding plasmids and immunoprecipitated with an anti-FLAG antibody. The

-22-

detection reagent is an anti-BAFF antibody. Lane 1: FLAG-tagged human soluble APRIL A105 (beginning at residue A105) + human full length BAFF; Lane 2: FLAG-tagged human soluble APRIL K110 (beginning at residue K110) + human full length BAFF; Lane 3: FLAG-tagged human soluble TWEAK A106 + human full length BAFF; Lane 4: FLAG-tagged human EDA A242 + human full length BAFF; Lane 5: empty control vector; Lane 6: molecular weight standards (Benchmark, LifeTechnologies) in kDa, 185, 119, 85, 62, 51, 38.2, 26.0, 20.2, 14.5, 9.1; Lane 7-11 correspond to Lanes 1-5, respectively, after immunoprecipitation with an anti-FLAG antibody; Lane 12: purified human FLAG-BAFF Q136, 5 ng.

In panel A, the detection with the anti-FLAG antibody, M2 shows that all the FLAG-epitope tagged soluble ligands are expressed and secreted into the cell culture of the transfected cells. The two APRIL constructs shown in lanes 1 and 2 are expressed about 5 fold lower than TWEAK (lane 3) or EDA (lane 4). No protein is visible in lane 5, which is the control vector lane. Lanes 7-11 represent the FLAG-tagged proteins after they are immunoprecipitated. Here both APRIL proteins (lanes 7 and 8), TWEAK (lane 9) and EDA (lane 10) are precipitated and detected by M2. Lane 12 is approximately 5 ng of FLAG-BAFF for a standard.

In panel B, lanes 1-5 represent the detection of BAFF in the co-transfected cell culture media. BAFF is expressed in combination with all the FLAG-epitope tagged soluble ligands and is slightly higher in the APRIL co-transfections (lanes 1 and 2). On the right side of the blot in panel B are the M2 immunoprecipitations detected with the anti-BAFF antibody, 53.14. Here, BAFF is only immunoprecipitated in combination with APRIL (lanes 7 and 8) and not TWEAK or EDA. The standard in lane 12 indicates the size of a soluble FLAG-BAFF molecule expressed in 293T cells, which is approximately the molecular weight of the naturally cleaved molecule. This demonstrates that BAFF and APRIL form a heteromeric complex. The co-immunoprecipitations have also been evaluated in the presence of 1 M NaCl and the results are the same.

### Example 2

This example describes the detection of APBF heteromers by immunoprecipitation following co-transfection of two soluble constructs into mammalian cells.

Methods:

-23-

Plasmids encoding the following human soluble TNF family ligands were constructed with the indicated N-terminal epitope tags beginning at the ligand amino acid residue indicated in a PCR3 based mammalian cell expression vector: FLAG-APRIL, beginning with residue A105 (plasmid # LT033) or H115 (plasmid # LT038),  
5 FLAG-TWEAK A106 (plasmid #PS288), myc-APRIL A105 (plasmid # JST557), and myc-BAFF Q136 (plasmid # JST556). Various constructs encoding FLAG-tagged ligands, full length murine APRIL(plasmid #LT022), or empty vector control (plasmid #CH269) were each co-transfected with the myc-BAFF Q136 construct into 293T cells using lipofectamine (Life Technologies, Gaithersburg, MD). At 48 hrs. post-  
10 transfection, conditioned media was collected and used for immunoprecipitation experiments. The immunoprecipitation samples contained 100 µl of conditioned media, 5 µg/ml of the anti-FLAG antibody M2 (Sigma, St Louis, MO) and 900 µl of DMEM containing 10% FCS, glutamine, Pen-Strep, G418 and sodium azide and were incubated at 4°C for 1 hour, with agitation. Then, 30 µl of ProteinA–Sepharose beads  
15 (Amersham Pharmacia, Piscataway, NJ) was added to the samples and the mixture was incubated overnight at 4°C with agitation. The beads were collected by centrifugation and then washed one time with the DMEM media described above and then 3 times with PBS. The final pellet containing the beads was then suspended in 2 X SDS non-reducing sample buffer and boiled for 5 minutes. The beads were spun out and 25 µl of  
20 the supernatant was loaded onto a 4-20% SDS-PAGE gradient gel (Novex, San Diego, CA). After the gel was transferred to Immobilon (Millipore, Bedford, MA) using a BioRad apparatus, the filters were blocked in 5% non-fat dry milk diluted in TBST for 1 hr at room temperature. The filter was then incubated with 1µg/ml of anti-myc antibody 9E10. The filter was washed with 3 changes of TBST and then incubated in a  
25 1:3000 dilution of anti-mouse IgG-HRP (Jackson ImmunoResearch, West Grove, PA) for 30 min. at room temperature. The filter was again washed 3 times and then detected using ECL reagents (Amersham Pharmacia, Piscataway, NJ). The filter was exposed to x-ray film for various lengths of time.

The results shown in Figure 4 show a western blot of the immunoprecipiations  
30 of conditioned media from cells co-transfected with plasmids encoding various soluble APRIL and soluble BAFF proteins and immunoprecipitated with an anti-FLAG-tagged antibody. The detection reagent for the western blot is an anti-myc antibody, 9E10.



-24-

Lanes 1-6, show western blots of straight conditioned media from cells co-transfected with plasmids encoding various human soluble TNF family ligands and human soluble myc-BAFF Q136. Lane 7 is a molecular weight marker. Lanes 8-12, show western blots of the conditioned media after immunoprecipitation with an anti-FLAG antibody. The detection reagent used an anti-MYC antibody, 9E10. Lane 1: 5 FLAG-tagged human soluble TWEAK A106 + human soluble myc-BAFF Q136; Lane 2: FLAG-tagged human soluble APRIL H115 + human soluble myc-BAFF Q136; Lane 3: MYC-tagged human soluble APRIL A105 + human soluble myc-BAFF Q136; Lane 4: FLAG-tagged human soluble APRIL A105 + human soluble myc-BAFF Q136; Lane 10 5: full length murine APRIL + human soluble myc-BAFF Q136; Lane 6: empty vector control + human soluble myc-BAFF Q136; Lane 7, molecular weight standards (Benchmark, LifeTechnologies) in kDa, 38.2, 26.0, 20.2, 14.5; Lanes 8-12 correspond to Lanes 1-5, respectively, after immunoprecipitation with an anti-FLAG antibody.

In lanes 1-6, the western blot of the conditioned media as detected by anti-MYC 15 antibody 9E10 shows that all co-transfected 293T cells express and secrete myc-Baff Q136 into the cell culture media in nearly equal amounts except for the FLAG-TWEAK + myc-Baff Q136 (lane 1) which shows significantly lower amounts of myc-BAFF. Lanes 8-12 show immunoprecipitation of conditioned media with anti-FLAG antibody followed by detection on western blot with anti-myc antibody 9E10. Lanes 10 20 and 12 show conditioned media of myc-BAFF co-transfected with myc-APRIL A105 or full length murine APRIL, respectively, and serve as negative controls in that neither APRIL construct contains the flag epitope and therefore were not immunoprecipitated by the anti-flag antibody. The FLAG-TWEAK co-transfection shows no band corresponding to myc-BAFF Q136, even upon overexposure, and therefore does not 25 interact with MYC-BAFF. Only lanes 9 and 11, those containing myc-Baff Q136 co-expressed with FLAG-APRIL molecules H115 and A105 respectively, show the myc-baff band after anti-FLAG immunoprecipitation. Bands of approximately 18kDa, the predicted size of myc-BAFF Q136, are observed in each lane. The intensity of the band co-expressed with FLAG-APRIL A87 (lane 3) greater than that co-expressed with 30 FLAG-APRIL H97 (lane 4). This indicates that only soluble FLAG-APRIL ligands were able to interact with soluble MYC-BAFF to form heteromeric complexes..

-25-

This demonstrates that soluble forms of BAFF and APRIL have the ability to form a heteromeric complex, and that no cell associated form appears to be required for heteromer formation..

Example 3: Production and isolation of APBF by Affinity Methods

5 Plasmids encoding the following human soluble TNF family ligands were constructed with N-terminal FLAG or 6xHis epitope tags beginning at the amino acid residue indicated in a PCR3 based mammalian cell expression vector: FLAG-APRIL, beginning with residue A87 (plasmid LT033) and RGS(H)6-BAFF Q134. These plasmids are then co-transfected into 293T cells using lipofectamine (Life  
10 Technologies, Gaithersburg, MD) and at 48 hrs. post-transfection, conditioned media is collected. The conditioned media is dialyzed against 50mM NaH<sub>2</sub>PO<sub>4</sub>, pH8.0; 300mM NaCl; 10mM imidazole and run over a Ni-NTA Superflow column (Qiagen, Valencia, CA). Homomers and heteromers containing the 6xHis tagged BAFF subunit bind to the Ni column; homomeric FLAG-APRIL molecules flow through. The column is  
15 washed with 50mM NaH<sub>2</sub>PO<sub>4</sub>, pH8.0; 300mM NaCl; 20mM imidazole with 5-10 column volumes. The column is eluted with 5 column volumes with 50mM NaH<sub>2</sub>PO<sub>4</sub>, pH8.0; 300mM NaCl; 250mM imidazole. The eluted material includes RGS(H)6-BAFF Q134 homomers and heteromers with FLAG-APRIL. This eluted material is applied to an M1 or M2 anti-FLAG Ab affinity column (Sigma, St. Louis,  
20 MO). A buffer exchange to 150mM NaCl – 50mM Tris pH7.0 is performed, and the buffer adjusted to 2mM CaCl<sub>2</sub> if using the M1 column (this Ab requires Ca for binding). The column is washed with 150mM NaCl – 50mM Tris pH7.0 ( with 2mM CaCl<sub>2</sub> for M1). The M1 column is eluted by incubating the column with 150mM NaCl – 50mM Tris pH7.0 – 2mM EDTA for 30 minutes, followed by aliquots of 150mM  
25 NaCl – 50mM Tris pH7.0-2mM EDTA, 10 min incubations, 6 times. Alternatively, both the M1 and M2 columns can be eluted by competition with FLAG peptide by allowing the column to drain completely and eluting 5 times with one column volume each of to 150mM NaCl – 50mM Tris pH7.0 containing 100µg/ml FLAG peptide. Eluted material will contain only native FLAG-APRIL:: RGS(H)6-BAFF Q134  
30 heteromers.

Alternatively, cell lines or cells transfected, as above, with plasmids encoding full length or untagged soluble APRIL and BAFF constructs could be used as a source to isolate APBF complexes with anti-peptide antibodies raised against regions of the

-26-

extracellular domains for APRIL and BAFF. These antibodies could be coupled to a resin by conventional means. Conditioned media or cell extracts of such cells could be run first over a column containing the coupled antibody (s) against one of the ligands, for example anti-BAFF antibody (s). In this instance, only homomers and heteromers  
5 containing a BAFF subunit bind to the anti-BAFF column; homomeric APRIL molecules flow through. After washing the column in 150 mM NaCl – 50 mM Tris pH7.0, the bound molecules could be eluted off by competition with the same BAFF peptide(s) used to raise the anti-BAFF antibody(s) by allowing the column to drain completely and eluting 5 times with one column volume each of to 150 mM NaCl – 50  
10 mM Tris pH 7.0 containing 100 µg/ml or greater the peptide(s). This eluate could be dialyzed to remove the peptide(s) and then similarly run over a column containing anti-peptide antibody(s) raised against the other ligand, in this example APRIL. ). In this instance, homomeric BAFF molecules would not bind to the column and flow through. Only the remaining APBF heteromers bind to the anti-BAFF column. These APBF  
15 heteromers could be similarly eluted by competition with the same APRIL peptide(s) used to generate the anti-APRIL antibody(s).

-27-

We claim:

1. An isolated polypeptide comprising an APRIL subunit linked via a non-covalent interaction to a BAFF subunit.
2. An isolated polypeptide comprising
  - 5 a) an APRIL subunit selected from the group consisting of:
    - i) partial human APRIL (SEQ ID NO: ), human APRIL (SEQ ID NO: ), partial murine APRIL (SEQ ID NO: ) and murine APRIL (SEQ ID NO: ) or
    - 10 ii) amino acid substitution variants of partial human APRIL (SEQ ID NO: ), human APRIL (SEQ ID NO: ), partial murine APRIL (SEQ ID NO: ) and murine APRIL (SEQ ID NO: ); and
  - b) linked via a non-covalent interaction to a BAFF subunit selected from the group consisting of:
    - 15 i) partial human BAFF (SEQ ID NO: ), human BAFF (SEQ ID NO: ), partial murine BAFF (SEQ ID NO: ) and murine BAFF (SEQ ID NO: ) or
    - ii) amino acid substitution variants of partial human BAFF (SEQ ID NO: ), human BAFF (SEQ ID NO: ), partial murine BAFF (SEQ ID NO: ) and murine BAFF (SEQ ID NO: ).
- 20 3. An isolated polypeptide comprising
  - a) an APRIL subunit comprising an amino acid sequence of an APRIL subunit encoded by mammalian DNA which hybridizes under high stringency conditions to a probe having the sequence of the complement of an APRIL nucleotide sequence selected from the group consisting of:
    - 25 i) partial human APRIL cDNA (SEQ ID NO: ), human APRIL cDNA (SEQ ID NO: ), partial murine APRIL cDNA (SEQ ID NO: ) and murine APRIL cDNA (SEQ ID NO: ) or
    - ii) a degenerate variant of a sequence selected from partial human APRIL cDNA (SEQ ID NO: ), human APRIL cDNA (SEQ ID NO: ),
    - 30 partial murine APRIL cDNA (SEQ ID NO: ) and murine APRIL cDNA (SEQ ID NO: );
  - b) linked via a non-covalent interaction to a BAFF subunit comprising an amino acid sequence encoded by mammalian DNA which hybridizes to a probe

-28-

under high stringency conditions having the sequence of the complement of an BAFF nucleotide sequence selected from the group consisting of:

- i) partial human BAFF cDNA (SEQ ID NO: \_), human BAFF cDNA (SEQ ID NO: \_), partial murine BAFF cDNA (SEQ ID NO: \_) and murine BAFF cDNA (SEQ ID NO: \_) or
  - ii) a degenerate variant of a sequence selected from partial human BAFF cDNA (SEQ ID NO: \_), human BAFF cDNA (SEQ ID NO: \_), partial murine BAFF cDNA (SEQ ID NO: \_) and murine BAFF cDNA (SEQ ID NO: \_).
4. An isolated polypeptide according to claim 1 and 2, further comprising more than one APRIL subunit linked non-covalently to a BAFF subunit.
5. The isolated polypeptide of claim 4, wherein two APRIL subunits are linked non-covalently to a BAFF subunit.
6. An isolated polypeptide according to claim 1, further comprising more than one BAFF subunits linked non-covalently to an APRIL subunit.
7. The isolated polypeptide of claim 6, wherein two BAFF subunits are linked non-covalently to an APRIL subunit.
8. A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
  - (a) An isolated APBF molecule or an active fragment thereof;
  - (b) A recombinant APBF molecule or an active fragment thereof; and
  - (c) an antibody specific for APBF or an active fragment thereof.
9. A method of inhibiting T-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
  - (a) An isolated APBF molecule or an active fragment thereof;
  - (b) A recombinant APBF molecule or an active fragment thereof; and
  - (c) an antibody specific for APBF or an active fragment thereof.

-29-

10. A method of inhibiting tumor cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- (a) An isolated APBF molecule or an active fragment thereof;
  - 5 (b) A recombinant APBF molecule or an active fragment thereof; and
  - (c) an antibody specific for APBF or an active fragment thereof.
11. A method of stimulating B-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- 10 (a) An isolated APBF molecule or an active fragment thereof;
  - (b) A recombinant APBF molecule or an active fragment thereof; and
  - (c) an antibody specific for APBF or an active fragment thereof.
- 15 12. A method of stimulating T-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- (a) An isolated APBF molecule or an active fragment thereof;
  - (b) A recombinant APBF molecule or an active fragment thereof; and
  - 20 (c) an antibody specific for APBF or an active fragment thereof.
13. The method according to claim 1 or 2, wherein the APBF polypeptide is soluble.
14. A pharmaceutical composition comprising a therapeutically effective amount of an isolated APBF polypeptide or a fragment thereof and a pharmaceutically acceptable carrier.
- 25 15. A method of therapeutically treating a mammal for a condition associated with undesired cell proliferation, said method comprising administering to said mammal a therapeutically effective amount of a composition comprising an APBF antagonist with a pharmaceutically acceptable recipient.
- 30

-30-

16. A method of inhibiting non-B-cell growth in a mammal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:

- (a) An isolated APBF molecule or an active fragment thereof;
- 5 (b) A recombinant APBF molecule or an active fragment thereof; and
- (c) an antibody specific for APBF or an active fragment thereof.

A

MPASSPFLAPKPPQNMGGPVREPALS<sup>TM</sup>VALWSWGAALGAVAGAMALLT 50  
QQTELQSLRRREVSRLQGTGGPSQNGEGYPWQSLPEQSSDALEAWENGERS 100  
RKRRAVLTQKQKKQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQA 150  
QGYGVRIQDAGVYLLYSQVLFQDVIFIMGQVVSREGQGRQETLFR CIRSM 200  
PSHPDRAYNSCYSAGVFHLHQDILSVIIPRARAKLNLSPHGTF LGFVKL 250

☆  
|SAPRII|

FIG. 1a



2/11

SEQ. ID NO: 1

1 GGTACGAGGC TTCCTAGAGG GACTGGAACC TAATTCCTCT GAGGCTGAGG  
51 GAGGGTGGAG GGTCTCAAGG CAACGCTGGC CCCACGACGG AGTGCCAGGA  
5 GACTAACAG TACCCCTTAGC TTGCTTTCCT CCTCCCTCCT TTTATTTTC  
151 AAGTTCCCTT TATTTCTCC TTGCGTAACA ACCTTCTTCC CTTCGCAAC  
201 ACTGCCCGTA CCTTACCCG CCCC GCCACC TCCTTGCTAC CCCACTCTTG  
251 AAACACAGC TGTGGCAGG GTCCCCAGCT CATGCCAGCC TCATCTCCTT  
301 TCTTGCTAGC CCCC AAGGG CCTCCAGGCA ACATGGGGGG CCCAGTCAGA  
351 GAGCCGGCAC TCTCAGTTGC CCTCTGGTTG AGTTGGGGGG CAGCTCTGGG  
401 GGCCGTGGCT TGTGCCATGG CTCTGCTGAC CCAACAACA GAGCTGCAGA  
451 GCCTCAGGAG AGAGGTGAGC CGGCTGCAGG GGACAGGAGG CCCTCCCAG  
501 AATGGGGAAG GGTATCCCTG GCAGAGTCTC CCGGAGCAGA GTTCCGATGC  
551 CCTGGAAGCC TGGAGAAATG GGGAGAGATC CCGGAAAGG GAGCAGTGC  
601 TCACCCAAA ACAGAAGAAG CAGCACTCTG TCCTGCACCT GGTTCCCATT  
651 AACGCCACCT CCAAGGATGA CTCGATGTG ACAGAGGTGA TGTGGCAACC  
701 AGCTCTTAGG CGTGGGAGAG GCCTACAGGC CCAAGGATAT GGTGTCCGAA  
751 TCCAGGATGC TGGAGTTTAT CTGCTGTATA GCCAGGTCTT GTTTCAGAC  
801 GTGACTTTCA CCA TGGGTCA GTGGTGTCT CGAGAAAGCC AAGGAAGCA  
851 GGAGACTCTA TTCCGATGTA TAAGAAGTAT GCCCTCCAC CCGACCGGG  
901 CCTACAAACAG CTGCTATAGC GCAGGTGTCT TCATTTACA CCAAGGGAT  
951 ATTCTGAGTG TCATAATTCC CCGGCAAGG GCGAAACTTA ACCTCTCTCC  
1001 ACATGGAACC TTCTGGGGT TTGTGA AACT GTGATTGTGT TATAAAGT  
1051 GGCTCCACG TTGGAAGACC AGGTGGGT A CATACTGGAGACAGCCAAGA  
1101 GCTGAGTATA TAAAGGAGAG GGAATGTGCA GGAACAGAGGCATCTTCCTG  
1151 GGTTTGGCTC CCGTTCCTC ACTTTCCCT TTTCA TTCC ACCCCCTAGA  
1201 CTTTGATTTT ACGGATATCT TGCTTCTGTT CCCC ATGGAG CTC CGAATTC  
1251 TTGCGTGTGT GTAGATGAGG GCGGGGGAC GGGCGCCAGG CATTGTTACG  
1301 ACCTGGTCGG GGCCCACTGG AAGCATCCAG AACAGCACCA CCATCTTA

FIG. 1b

3/11

30 SEQ ID NO: 2

1 MPASSPELLA PKGPPGNMGG PVREPALSVA LWLSWGAALG AVACAMALLT  
51 QQTELQSLRR EVSRLQGTGG PSQNGEGYPW QSLPEQSSDA LEAWENGERS  
101 RKRRAVLTQK QKKQHSVLHL VPINATSKDD SDVTEVMWQP ALRRGRGLQA  
151 QGYGVRIQDA GYLLYSQVL FQDVTFTMGQ VVSREGQGRQ ETLFRCIRSM  
201 PSHPDRA YNS CYSAGVFHLH QGDILSVIIP RARAKLNLSP HGTFLGFVKL

FIG. 1C

SEQ ID NO: 3

1	GAATTCGGCA	CGAGGCTCCA	GGCCACATGG	GGGGTCAGT	CAGAGAGCCA
51	GCCCTTTCGG	TTGCTCTTTG	GTTGAGTTGG	GGGCAGTTC	TGGGGGCTGT
101	GACTTGTGCT	GTCGCACTAC	TGATCCAACA	GACAGAGCTG	CAAAGCCCTAA
151	GGCGGGAGGT	GAGCCGGCTG	CAGCGGAGTG	GAGGGCCTTC	CCAGAAGCAG
201	GGAGAGCGCC	CATGGCAGAG	CCTCTGGGAG	CAGAGTCCTG	ATGTCCTGGA
251	AGCCTGGAAG	GATGGGGCGA	AATCTCGGAG	AAGGAGAGCA	GTAATCACCC
301	AGAAGCACAA	GAAGAAGCAC	TCAGTCCTGC	ATCTTGTTCC	AGTTAACATT
351	ACCTCCAAGG	ACTCTGACGT	GACAGAGGTG	ATGTGGCAAC	CAGTACTTAG
401	GCGTGGGAGA	GGCCCTGGAG	GCCCAGGGAG	ACATTGTACG	AGTCTGGGAC
451	ACTGGAAATT	ATCTGCTCTA	TAGTCAGGTC	CTGTTTCATG	ATGTGACTTT
501	CACAAATGGT	CAGGTGGTAT	CTCGGGAAGG	ACAAGGGAGA	AGAGAAACTC
551	TATTCCGATG	TATCAGAAGT	ATGCCCTTCTG	ATCCTGACCG	TGCCATACAT
601	AGCTGCTACA	GTGCAGGTGT	CTTTCATTTA	CATCAAGGGG	ATATTATCAC
651	TGTCAAAATT	CCACGGGCAA	ACGCAAAACT	TAGCCTTTCT	CCGCATGGAA
701	CATTCCCTGG	GTTTGTGAAA	CTATGATTGT	TATAAAGGGG	GTGGGGATTT
751	CCCATTCCAA	AAACTGGCTA	GACAAAGGAC	AAGGAACGGT	CAAGAACAGC
801	TCTCCATGGC	TTTGCCCTTGA	CTGTTGTTCC	TCCCTTTGCC	TTTCCCGCTC
851	CCACTATCTG	GGCTTTGACT	CCATGGATAT	TAAAAAAGTA	GAATATTTTG
901	TGTTTATCTC	CCAAAA			

FIG. 1d

SEQ ID NO: 4

1 MGGSVREPAL SVALWLSWGA VLGAVTCAVA LLIQQTELOQ LRREVSRLQR  
51 SGGPSQKQGE RPWQSLWEQS PDVLEAWKDG AKSRRRRRAVL TQKHKKKHSV  
101 LHLVPVNITS KSDVTEVMW QPVLRRGRGP GGQGDIVRVW DTGIYLLYSQ  
151 VLFHDVTFTM GQVVSREGQG RRETLEFRCIR SMPSPDPDRAY NSCYSAGVFH  
201 LHQGDIIITVK IPRANAKLSL SPHGTFGLGFV KL

FIG. 1e

SEQ. ID. NO. 5	
1	TGCCAAGCCC TGCCATGTAG TGCACGCAGG ACATCAACAA ACACAGATAA
51	CAGGAAATGA TCCATTCCCT GTGGTCACTT ATTCTAAAGG CCCCAACCTT
101	CAAAGTTCAA GTAGTGATAT GGATGACTCC ACAGAAAGGG AGCAGTCACG
151	CCTTACTTCT TGCCTTAAGA AAAGAGAAGA AATGAAACTG AAGGAGTGTG
201	TTTCCATCCT CCCACGGAAG GAAAGCCCCCT CTGTCCGATC CTCCAAGAC
251	GGAAAGCTGC TGGCTGCAAC CTTGCTGCTG GCACTGCTGT CTTGCTGCCT
301	CACGGTGGTG TCTTTCTACC AGGTGGCCGC CCTGCAAGGG GACCTGGCCA
351	GCCTCCGGGC AGAGCTGCAG GGCCACCACG CGGAGAAGCT GCCAGCAGGA
401	GCAGGAGCCC CCAAGGCCGG CCTGGAGGAA GCTCCAGCTG TCACCGCGGG
451	ACTGAAATC TTTGAACCCAC CAGCTCCAGG AGAAGGCAAC TCCAGTCAGA
501	ACAGCAGAAA TAAGCGTGCC GTTCAGGGTC CAGAAGAAAC AGTCACTCAA
551	GACTGCTTGC AACTGATTGC AGACAGTGAA ACACCAACTA TACAAAAGG
601	ATCTTACACA TTTGTTCAT GGCTTCTCAG CTTTAAAGG GGAAGTGCCC
651	TAGAAGAAAA AGAGAATAAA ATATTGGTCA AAGAACTGG TTACTTTT
701	ATATATGGTC AGGTTTATA TACTGATAAG ACCTACGCCA TGGGACATCT
751	AATTCAGAGG AAGAAGGTCC ATGTCTTTGG GGATGAATTG AGTCTGGTGA
801	CTTTGTTCG ATGTATTCAA AATATGCCCTG AAACACTACC CAATAATTCC
851	TGCTATTTCAG CTGGCATTCG AAAACTGGAA GAAGGAGATG AACTCCAAC
901	TGCAATACCA AGAGAAAATG CACAAATATC ACTGGATGGA GATGTCACAT
951	TTTTTGGTGC ATTGAAACTG CTGTGACCTA CTTACACCAT GTCTGTAGCT
1001	ATTTTCCTCC CTTTCTCTGT ACCTCTAAGA AGAAAGAATC TAACTGAAAA
1051	TA

FIG. 2a

7/11

SEQ. ID NO. 6

1	MDDSTEREQS	RLTSLCKKRE	EMKLKECVSI	LPRKESPSVR	SSKDGKLLAA
51	TLLLLALLSCC	LTVVSFYQVA	ALQGDLASLR	AELQGHHAEK	LPAGAGAPKA
101	GLEEAPAVTA	GLKIFEPAP	GEGNSSQNSR	NKRAVQGPEE	TVTQDCLQLI
151	ADSETPTIQK	GSYTFVPWLL	SFKRGSAL EE	KENKILVKET	GYFFIYGQVL
201	YTDKTYAMGH	LIQRKKVHVF	GDELSLVTLF	RCIQNMPE TL	PNNSCYSAGI
251	AKLEEGDELQ	LAIPRENAQI	SLDGDVTFFG	ALKLL	

30

FIG. 2b

35	SEQ. ID NO. 7	1	GTGGTCACTT	ACTCCAAGG	CCTAGACCTT	CAAAGTGCTC	CTCGTGGAAT
		51	GGATGAGTCT	GCAAAGACCC	TGCCACCACC	GTGCCCTCTGT	TTTGTGCTCCG
		101	AGAAAGGAGA	AGATATGAAA	GTGGGATATG	ATCCCATCAC	TCCGCAGAAG
		151	GAGGAGGGTG	CCTGGTTTGG	GATCTGCAGG	GATGGAAGGC	TGCTGGCTGC
		201	TACCCCTCCTG	CTGGCCCTGT	TGTCCAGCAG	TTTCACACGG	ATGTCCCTTGT
40		251	ACCAGTTGGC	TGCCTTGCAA	GCAGACCTGA	TGAACCTGCG	CATGGAGCTG
		301	CAGAGCTACC	GAGGTTTCAGC	AACACCAGCC	GCCGCGGGTG	CTCCAGAGTT
		351	GACCGCTGGA	GTCAAACCTCC	TGACACCGGC	AGCTCCTCGA	CCCCACAAC
		401	CCAGCCGCGG	CCACAGGAAC	AGACGCGCTT	TCCAGGGACC	AGAGGAAACA
45		451	GAACAAGATG	TAGACCTCTC	AGCTCCTCCT	GCACCATGCC	TGCCCTGGATG
		501	CCGCCATTCT	CAACATGATG	ATAATGGAA	GAACCTCAGA	AACAGAACTT
		551	ACACATTTGT	TCCATGGCTT	CTCAGCTTTA	AAAGAGGAAA	TGCCCTGGAG
		601	GAGAAAGAGA	ACAAATAGT	GGTGAGGCAA	ACAGGCTATT	TCTTCATCTA
		651	CAGCCAGGTT	CTATACACGG	ACCCCATCTT	TGCTATGGGT	CATGTCATCC
50		701	AGAGGAAGAA	AGTACACGTC	TTTGGGGACG	AGCTGAGCCT	GGTGACCCCTG
		751	TTCCGATGTA	TTCAGAAATAT	GCCCAAAACA	CTGCCCAACA	ATTCCTGCTA
		801	CTCGGCTGGC	ATCGCGAGGC	TGGAAGAAGG	AGATGAGATT	CAGCTTGCAA
		851	TTCCCTCGGA	GAATGCACAG	ATTTCACGCA	ACGGAGACGA	CACCTTCTTT
		901	GGTGCCCTAA	AACTGCTGTA	ACTCACTTGC	TGGAGTGCGT	GATCCCCCTC
55		951	CCTCGTCTTC	TCTGTACCTC	CGAGGGAGAA	ACAGACGACT	GGAAAAACTA
		1001	AAAGATGGGG	AAAGCCGTCA	GCGAAAGTTT	TCTCGTGACC	CGTTGAATCT
		1051	GATCCAAACC	AGGAAATATA	ACAGACAGCC	ACAACCGAAG	TGTGCCCATGT
		1101	GAGTTATGAG	AAACGGAGCC	CGCGCTCAGA	AAGACCGGAT	GAGGAAGACC
		1151	GTTTTCCTCCA	GTCCTTTGCC	AACACGCACC	GCAACCTTGC	TTTTTTGCCCTT

FIG. 2C

9/11

1201 GGGTGACACA TGTTCAGAAAT GCAGGGAGAT TTCCTTGTTT TGCGATTGTC  
1251 CATGAGAAGA GGGCCACAAA CTGCAGGTCA CTGAAGCATT CACGCTAAGT  
1301 CTCAGGATTT ACTCTCCCTT CTCTATGCTAA GTACACACAC GCTCTTTTCC  
1351 AGGTAAC TAC TATGGGATAC TATGGAAAGG TTGTTTGTTT TTAATCTAG  
1401 AAGTCTTGAA CTGGCAATAG ACAAAAATCC TTATAAATTC AAGTGTAATA  
1451 TAAACTTAAT TAAAAGGTT TAAGTGTC

5

SEQ. ID NO. 8

1 MDESAKTLPP PCLCFCSEKG EDMKVGYPDPI TPQKEGAWF GICRDGRLLA  
51 ATLLALLSS SFTAMSLYQL AALQADLMNL RMELQSYRGS ATPAAAGAPE  
101 LTAGVKLLTP AAPRPHNSSR GHRNRRAFQG PEETEQDVDL SAPPAPCLPG  
151 CRHSQHDDNG MNLNRRTYTF VPWLLSFKRG NALKEENKI VVRQTGYFFI  
201 YSQVLYTDPI FAMGHVIQK KHVHFGDELS LVTLFRCIQN MPKTLPNNSC  
251 YSAGIARLEE GDEIQLAIPR ENAQISRNGD DTFFGALKLL

10

15

FIG. 2d



10/11

1 2 3 4 5 6 7 8 9 10 11 12




FIG. 3a

1 2 3 4 5 6 7 8 9 10 11 12




FIG. 3b

11/11




FIG. 4

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number  
**WO 01/58949 A3**

(51) International Patent Classification<sup>7</sup>: C07K 14/525,  
C12N 5/02, A61K 38/17

(74) Agent: LINKKILA, Timothy, P.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(21) International Application Number: PCT/US01/04121

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/181,670 11 February 2000 (11.02.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): RENNERT, Paul, D. [US/US]; 278 Ridge Street, Millis, MA 02054 (US). THOMPSON, Jeffrey, S. [US/US]; 60 Newcomb Road, Stoneham, MA 02180 (US). AMBROSE, Christine [US/US]; 197 Wakefield Street, Reading, MA 01867 (US). CACHERO, Teresa, G. [ES/US]; 105 Longwood Avenue, Brookline, MA 02446 (US).

(88) Date of publication of the international search report:  
7 March 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: HETEROLOGOUS POLYPEPTIDE OF THE TNF FAMILY

(57) Abstract: A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as "APBF" has been identified.



WO 01/58949 A3

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/04121

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/525 C12N5/02 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MARSTERS S A ET AL: "INTERACTION OF THE TNF HOMOLOGUES BLYS AND APRIL WITH THE TNF RECEPTOR HOMOLOGUES BCMA AND TACI" CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 10, no. 13, 29 June 2000 (2000-06-29), pages 785-788, XP000992744 ISSN: 0960-9822 page 787, column 1 --- -/--	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

20 September 2001

Date of mailing of the international search report

27/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Keller, Y

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04121

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MACKAY F ET AL: "MICE TRANSGENIC FOR BAFF DEVELOP LYMPHOCYTIC DISORDERS ALONG WITH AUTOIMMUNE MANIFESTATIONS" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 190, no. 11, 1999, pages 1697-1710, XP000915435 ISSN: 0022-1007 abstract page 1706, column 1 tables 1,2</p>	1-16
Y	<p>--- SCHNEIDER P ET AL: "BAFF, A NOVEL LIGAND OF THE TUMOR NECROSIS FACTOR FAMILY, STIMULATES B CELL GROWTH" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747-1756, XP000915409 ISSN: 0022-1007 abstract page 1748, column 1, paragraph 1 page 1750, column 1 page 1753, column 1-2</p>	1-16
Y	<p>--- HAHNE M ET AL: "APRIL, a new ligand of the tumor necrosis factor family, Stimulates tumor cell growth" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, 21 September 1998 (1998-09-21), pages 1185-1190, XP002093077 ISSN: 0022-1007 abstract page 15, line 30 -page 16, line 9 page 25, line 30 -page 26, line 20 page 1187, column 2, paragraph 2 -page 1188, column 2, paragraph 1</p>	1-16
Y	<p>--- WO 99 12965 A (TSCHOPP JURG ;BIOGEN INC (US)) 18 March 1999 (1999-03-18) page 3, line 16 -page 4, line 5 page 8, line 15 -page 9, line 9 page 15, line 17 -page 15, line 23 page 15, line 30 -page 16, line 9 page 25, line 30 -page 26, line 20 figure 3 figure 4 figure 5 -----</p>	1-16

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/04121

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9912965 A	18-03-1999	AU 9315298 A	29-03-1999
		AU 9316298 A	29-03-1999
		BR 9812433 A	26-09-2000
		BR 9812634 A	22-08-2000
		CN 1269832 T	11-10-2000
		CN 1270632 T	18-10-2000
		EE 200000147 A	15-02-2001
		EE 200000148 A	15-02-2001
		EP 1012270 A	28-06-2000
		EP 1027431 A	16-08-2000
		HU 0004034 A	28-03-2001
		HU 0004611 A	28-04-2001
		NO 20001240 A	10-05-2000
		NO 20001242 A	11-05-2000
		PL 339463 A	18-12-2000
		PL 339740 A	02-01-2001
		SK 3542000 A	14-08-2000
		TR 200000654 T	21-07-2000
		TR 200000669 T	21-08-2000
		WO 9912964 A	18-03-1999